Xeris Biopharma Holdings Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Xeris Biopharma Holdings Inc had 111.75M in cash and cash equivalents.

Xeris Biopharma Holdings Inc reported 369.84M in total liabilities as of the latest reported quarter, including 109.57M in current liabilities and 260.26M in non-current liabilities.

As of the latest reported quarter, Xeris Biopharma Holdings Inc's total assets were 383.53M, consisting of 240.31M in current assets and 143.21M in non-current assets.

Xeris Biopharma Holdings Inc reported 13.69M in total shareholders' equity as of the latest reported quarter.